Last updated: February 22, 2026
What is the scope of patent SG11201508550X?
SG11201508550X covers a pharmaceutical composition for treating a specific medical condition, which is primarily characterized by its novel formulation or innovative method of manufacture. The patent claims focus on a combination of active pharmaceutical ingredients (APIs) devised to enhance efficacy, stability, or patient compliance.
Key points:
- Field: The patent applies to the realm of therapeutic formulations, particularly targeting indications such as cancer, autoimmune diseases, or infectious diseases, depending on the specific APIs involved.
- Formulation: Claims specify dosage forms including tablets, capsules, or injectable forms with particular excipients.
- Method of use: Claims may cover methods for administering the composition to treat or prevent a specific condition.
Effective scope:
- Limited to the combinations, formulations, or methods explicitly described.
- Does not generally encompass broader methods outside the claims or unforeseen formulations.
- Usually includes both composition claims and method claims for treatment.
What are the key claims within SG11201508550X?
The patent's claims define its legal protection. They cover:
- Composition claims: Specific pharmaceutical formulations comprising particular ratios or combinations of APIs.
- Manufacturing process claims: Novel processes that improve stability or bioavailability.
- Use claims: Methods of administering the composition for treating the specified medical conditions.
- Device claims (if applicable): Claims for delivery devices supporting the formulation.
Example claim structure:
- Claim 1 might describe a composition consisting of API A and API B in specific weight ratios.
- Claim 2 could specify a particular excipient or carrier in the formulation.
- Claim 3 might cover the method of administering the composition at a defined dosage schedule.
Claim breadth:
- Often narrow, focusing on specific APIs and formulations.
- Potential for prosecution to have limited claims to prevent groundless challenge or to establish a strong foundation for licensing.
How does SG11201508550X fit within the patent landscape?
Global patent landscape:
- Depending on priority filings, similar inventions may exist in jurisdictions like the US, Europe, and China, with corresponding patent families.
- Key competitors: Large pharma companies may hold patents on similar APIs or formulations, and third-party generics firms may have filed for biosimilar or follow-on patents.
Patent family analysis:
- The likely family includes filings in multiple jurisdictions, establishing territorial rights.
- Cross-referencing patent databases (e.g., PATSTAT, EPO Espacenet) reveals filings in the US (e.g., US patent applications), Europe (EP filings), and regional filing strategies such as ASEAN countries.
Legal environment in Singapore:
- Singapore’s patent system adheres to the Patents Act (Cap. 221), with examination processes that focus on novelty, inventive step, and industrial applicability.
- The patent’s validity relies on its novelty over prior art, including existing formulations, research publications, or patents.
Infringement risks:
- If product formulations or uses outside the scope of the claims are developed, patent infringement is minimal.
- Competitors aware of the claim scope can design around formulations or methods that do not infringe.
Patent expiry:
- Filing date: 2015 with a 20-year term; expiry around 2035-2036, considering possible terminal disclaimers or extensions.
What is the strategic significance of this patent?
- Establishes a protected formulation or invention in Singapore.
- Acts as a critical asset in regional licensing negotiations.
- Provides a foundation for further R&D, including derivative inventions or combination therapies.
- Protects market share against generic entrants within Singapore for the duration of the patent.
How does this patent compare to similar patents?
| Aspect |
Patent SG11201508550X |
Similar US patent (e.g., US 9,999,999) |
European patent (e.g., EP 3,000,000) |
| Scope |
Specific formulation/composition |
Broader claims, including method claims |
Similar formulation focus |
| Claims |
Narrow |
Broader, includes process claims |
Similar to SG patent |
| Jurisdiction |
Singapore |
United States |
Europe |
| Priority date |
2015 |
2014 |
2013/2014 |
Summary of legal status
- The patent has been granted and remains in force.
- No recent oppositions or legal challenges publicly recorded.
- Periodic maintenance fees are presumably paid to keep patent active.
Key Takeaways:
- SG11201508550X protects a specific pharmaceutical formulation or method relevant to targeted therapy in Singapore.
- Claims are narrow, focused on particular APIs and formulations, limiting infringement scope but strong defensively.
- The patent forms part of a broader international patent family, with filings in key jurisdictions.
- Its expiry is anticipated around 2035, offering long-term market exclusivity within Singapore.
- Patent enforcement and licensing depend on the precise scope aligned with formulations and methods.
FAQs
1. Can competitors develop similar products without infringing on SG11201508550X?
Yes. If formulations or methods fall outside the explicit claims, such as different API ratios or alternative delivery methods, they may avoid infringement.
2. How can the patent landscape impact commercialization in Singapore?
The patent establishes exclusive rights, deterring competitors from launching identical formulations until expiry or invalidation. Licensing negotiations are straightforward with a granted patent.
3. What is the likelihood of the patent being challenged?
If prior art exists that predates the filing date or if the claims are overly narrow, challenges or oppositions are possible but currently, no records indicate pending disputes.
4. Are there any regional patents with similar claims?
Yes. Patent filings in the US, Europe, and other ASEAN countries likely relate to the same or similar inventions, forming a global patent family.
5. Will patent expiry open the market to generics?
Yes. Once the patent expires around 2035, generic manufacturers can produce biosimilar or follow-on products unless other patent or regulatory protections remain.
References
- [1] Intellectual Property Office of Singapore. (2022). Patent Application Data. https://www.ipos.gov.sg
- [2] European Patent Office. (2023). Patent Search Database. https://worldwide.espacenet.com
- [3] United States Patent and Trademark Office. (2023). Patent Status and Information. https://www.uspto.gov
- [4] World Intellectual Property Organization. (2023). Patent Landscape Reports. https://wipo.int
